Clinical Trial Update: The Safety and Efficacy of Transarterial Chemoembolization (TACE) + Lenvatinib + Programmed Cell Death Protein 1 (PD-1) Antibody of Advanced Unresectable Hepatocellular Carcinoma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial assessing safety and efficacy of transarterial chemoembolization combined with lenvatinib and a PD-1 antibody in advanced unresectable hepatocel…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• LENVIMA (lenvatinib)
• PD-1 antibody (PD-1 inhibitor)

Snippet

Sponsor: Xinrui Zhu，MD | Conditions: Hepatocellular Carcinoma Non-resectable, Transarterial Chemoembolization | Phase 1, Phase 2 | Status: COMPLETED